建议提案办理见成效丨助力创新药发展加速跑——国家医保局积极推动落实代表委员建议提案

Core Viewpoint - The National Healthcare Security Administration (NHSA) is actively promoting the development of innovative drugs in response to suggestions from national representatives and committee members, aiming to enhance public health and the pharmaceutical industry's high-quality development [2][4]. Group 1: Innovative Drug Development - The NHSA has facilitated the inclusion of innovative drugs like Inalise tablets into insurance coverage, significantly reducing out-of-pocket expenses for patients [2]. - In 2025, 76 innovative drugs were approved for market entry, with overseas licensing agreements exceeding $130 billion, indicating robust industry growth [2]. - The NHSA has implemented 16 measures to support innovative drug development, addressing areas such as research support, insurance access, clinical application, and diversified payment systems [3]. Group 2: Policy Implementation and Feedback - The NHSA has resolved or adopted 206 issues related to suggestions and proposals in 2025, issuing 29 related policy measures and incorporating 40 suggestions from representatives and committee members [3][4]. - The NHSA has established a comprehensive process for handling suggestions, ensuring effective communication and feedback throughout the implementation stages [4]. - The NHSA's proactive approach has led to timely and high-quality responses to all national representatives' suggestions and committee proposals, covering key areas such as insurance funding mechanisms and drug procurement policies [4]. Group 3: Future Directions - The NHSA plans to continue innovating its methods and strengthen communication with representatives and committee members to address key issues and enhance the effectiveness of suggestion handling [5].